AI Summary
5 min readTarget Shows Signs of Life, Moderna Scores a Cancer Breakthrough, and OpenAI's Growth Raises Questions
Target's earnings this morning delivered a much-needed jolt of good news for a retailer that has been struggling for years. Same-store sales rose 3.8%, total sales climbed 5.3%, and earnings per share doubled — though that headline number came with a major asterisk. A one-time $994 million tariff refund added $1.65 per share to the bottom line. Strip that away, and fundamental earnings still grew 20% year over year. The stock is up nearly 60% year to date, suggesting the market has already priced in a meaningful recovery.
Target's Turnaround: Real Progress or Just a Pulse?
The numbers show genuine operational improvement, but the details reveal how much work remains. Target has lowered prices on more than 10,000 items to attract budget-conscious shoppers, and the company is leaning hard into digital and service-based revenue. Traditional in-store sales grew 2.7%, while digital sales jumped 8.7%. Same-day deliveries surged 25%, and non-merchandise revenue rose 20%. New CEO Michael Fiddelke, who took over earlier this year, is implementing a multi-billion dollar turnaround strategy that includes both price cuts and store investments.
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
Never miss an episode of Motley Fool Hidden Gems Investing
Get every new episode summarized in your inbox — free, ~5 minutes to read.
No spam. Unsubscribe anytime.
What you'll learn
- 1 (00:18) **Target Earnings: A Pulse, But Not a Cure** - Target reports a 5.3% sales increase and a 100% jump in EPS, but the headline number is misleading.
- 2 (03:50) **Target's Identity Crisis** - The hosts debate whether Target's current strategy is sustainable or just "whack-a-mole."
- 3 (07:29) **Moderna's Historic Cancer Vaccine Breakthrough** - Moderna stock surges 140-160% on phase 3 trial results for a personalized mRNA cancer vaccine.
- 4 (10:32) **Caution on Moderna: Hope vs. Hype** - The team warns against chasing the stock after the massive one-day pop.
- 5 (15:47) **OpenAI's Slowing Growth Raises Red Flags** - OpenAI reports 18% quarter-over-quarter revenue growth, which is seen as disappointing for a supposed hyper-growth company.
- 6 (18:02) **The AI IPO Arms Race: OpenAI vs. Anthropic** - The hosts analyze the strategic motivations behind the potential IPOs of both AI giants.
+ Full timestamped outline available in the app
Show Notes
Target reported solid earnings this morning, which is a great sign for the consumer, but the big news today was from Moderna. The company’s clinical trial results for a cancer vaccine were so encouraging it was fast tracked through the trial and, while there are questions, this could change how we look at cancer in the future. We discuss why the stock is up over 100%. Plus, we end the show with the latest from OpenAI and Anthropic.
Travis Hoium, Lou Whiteman, and Rachel Warren discuss:
- Target Earnings
- Is Target Stock a Buy?
- Moderna’s HUGE News
- Scaling Qs
- Is AI Growth Slowing?
- Speed Running to an IPO
Companies discussed: Target (TGT), Moderna (MRNA), Merck (MRK).
Host: Travis Hoium
Guests: Lou Whiteman, Rachel Warren
Engineer: Kristi Waterworth
Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.
We’re committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices
More from this podcast
Motley Fool Hidden Gems Investing →